Ratings Morphic Holding, Inc.

Equities

MORF

US61775R1059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
28.62 ^USD	-1.75%		-4.28%	-0.90%

Apr. 25	Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 19	Morphic Holding Names Simon Cooper as Chief Medical Officer	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 22% by 2026.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHIC HOLDING, INC.	-0.90%	1.43B	C-
MODERNA, INC.	+17.96%	44.96B	B-
LONZA GROUP AG	+48.77%	41.85B	A
IQVIA HOLDINGS INC.	+1.17%	42.65B	B
CELLTRION, INC.	-4.27%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B	B
BIO-TECHNE CORPORATION	+4.86%	12.75B	B+
MEDPACE HOLDINGS, INC.	+27.29%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes